Recombinant human bone morphogenetic proteins in the treatment of fractures.
Recently, several prospective randomized clinical trials have resulted in the publication of critical studies on the efficacy of recombinant human morphogenetic proteins BMP-2 (rhBMP-2) and BMP-7 (OP-1) in spinal fusion and fracture healing. The clinical use of BMPs is now in its infancy and understanding the mechanism and the appropriate application of these proteins is necessary for all practicing orthopedic surgeons. This article will revisit some of the early studies using rhBMPs and review the current literature on their role in fracture healing.
Kain
Michael S H
MS
Department of Orthopedic Surgery, Boston University Medical Center, 720 Harrison Avenue, Suite 808, Boston, MA 02118, USA. Michael.Kain@bmc.org
Einhorn
Thomas A
TA
D000818:Animals; D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D017102:Fracture Healing / Q000187:drug effects; D050723:Fractures, Bone / Q000628:therapy*; D005599:Fractures, Ununited / Q000628:therapy; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013123:Spinal Fusion; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
C525819:BMP7 protein, human; D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2